A pharmacist-initiated method to improve venous thromboembolic prophylaxis rates in medically ill patients

Journal of Pharmacy Practice

Volumn 19, Issue 5, 2006, Pages 275-279

  Stark, Jennifer E ^a   Vesta, Kimi S ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

Clinical pharmacist; Internal medicine; Prophylaxis; Venous thromboembolism

Indexed keywords

ENOXAPARIN; HEPARIN DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; FEMALE; HUMAN; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PHARMACIST; PHYSICIAN; PROPHYLAXIS; RISK FACTOR; SCREENING; TEACHING; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VENOUS THROMBOEMBOLISM;

EID: 34248174772     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190006295398     Document Type: Article

References (21)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. Chest. 2004 ; 126: 338S - 400S.
2. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992 ; 340: 152-156.
3. Turpie Agg, Gallus AS, Hoek JA A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. N Engl J Med. 2001 ; 344: 619-625.
4. Collins R., MacMahon S., Flather M., et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomized trials. BMJ. 1996 ; 313: 652-659.
5. Sandset PM, Dahl T., Stiris M., Rostad B., Scheel B., Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep vein thrombosis in acute ischemic stroke. Semin Thromb Hemost. 1990 ; 16: 25S - 33S.
6. Samama MM, Cohen TA, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999 ; 341: 793-800.
7. Mismetti P., Laport-Simitsidis S., Tardy B., et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low molecular weight heparins: a meta-analysis of randomized clinical trials. Thromb Haemost. 2000 ; 83: 14-19.
8. Kleber FX, Witt C., Vogel G., Koppenhagen K., Schomaker U., Flosbach CW Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003 ; 145: 614-621.
9. Leizorovicz A., Cohen AT, Turpie A., Olsson C., Vaitkus PT, Goldhaber SZ Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004 ; 110: 874-879.
10. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest. 2001 ; 120: 1964-1971.
11. Bratzler DW, Raskob GE, Murray CK, Bumpus LJ, Piatt DS Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. Arch Intern Med. 1998 ; 158: 1909-1912.
12. Stark JE, Kilzer WJ Venous thromboembolic prophylaxis in hospitalized medical patients. Ann Pharmacother. 2004 ; 38: 36-40.
13. Enders JM, Dobesh PP, Abu-Shanab JR, Lakamp JE Utilization of venous thromboembolism prophylaxis in acute medical illness. Pharmacotherapy. 2002 ; 22: 1344. Abstract 118.
14. Rahim SA, Panju A., Pai M., Ginsberg J. Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review. Thromb Res. 2003 ; 111: 215-219.
15. Stinnett JM, Pendleton R., Skordos L., Wheeler M., Rodgers GM Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. Am J Hematol. 2005 ; 78: 167-172.
16. Goldhaber SZ, Tapson VT, for the DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004 ; 93: 259-262.
17. Levine MN, Raskob G., Beyth RJ, Kearon C., Schulman S. Hemorrhagic complications of anticoagulant treatment. Chest. 2004 ; 126: 287S - 310S.
18. Tooher R., Middleton P., Pham C., et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg. 2005 ; 241: 397-415.
19. de Lissovoy G., Subedi P. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective. Am J Manag Care. 2002 ; 8: 1082-1088.
20. Hauch O., Khatter SC, Jorgensen LN Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery. Semin Thromb Hemost. 1991 ; 17: 280-283.
21. Oster G., Truden RL, Colditz GA Cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA. 1987 ; 257: 203-205.